Products for Research Use Only
RegisterLogin

CDK7-IN-20

CAT: 0804-HY-151878Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-151878Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CDK7-IN-20 is a potent, selective and irreversible CDK7 (CDK) inhibitor with an IC50 value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research[1].
CAS Number
3034210-97-1
UNSPSC
12352005
Target
CDK; GSK-3
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/cdk7-in-20.html
Solubility
10 mM in DMSO
Smiles
C=CC(NC1=CC=C(C=C1)C(NC2=NNC3=C2C=C(C=C3)C4=CC(NC[C@H](C5=CC=CC=C5)O)=CN=C4)=O)=O
Molecular Formula
C30H26N6O3
Molecular Weight
518.57
References & Citations
[1]Bowen Yang, et al. Discovery of Novel N- (5- (Pyridin-3-yl) -1 H-indazol-3-yl) benzamide Derivatives as Potent Cyclin-Dependent Kinase 7 Inhibitors for the Treatment of Autosomal Dominant Polycystic Kidney Disease. J Med Chem. 2022 Nov 17.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK1; CDK12; CDK2; CDK3; CDK5; CDK6; CDK7; CDK9; GSK-3β

Related Products

CatalogName
HY-144175CDK7-IN-12
HY-153950CDK7-IN-22
HY-145402CDK7-IN-7
HY-145424CDK7-IN-10
HY-147602CDK7-IN-17
HY-153278-01CDK7-IN-21
HY-143586CDK7-IN-8
HY-139342-01CDK7-IN-4
HY-162416CDK7-IN-27
HY-145394CDK7-IN-6

Alternative Products

CatalogName
GTR19212344-01CDK7-IN-20
C2577-08Cdk7
70R-33496CDK7 antibody
BA3830-1CDK7-IN-2
T39943CDK7-IN-6
T63301-01CDK7-IN-18

Popular Products